Cost-effective purification process development for chimeric hepatitis B core (HBc) virus-like particles assisted by molecular dynamic simulation

被引:6
|
作者
Zhang, Bingyang [1 ]
Yin, Shuang [1 ]
Wang, Yingli [2 ]
Su, Zhiguo [3 ]
Bi, Jingxiu [1 ]
机构
[1] Univ Adelaide, Fac Engn Comp & Math Sci, Sch Chem Engn & Adv Mat, Adelaide, SA 5005, Australia
[2] Shanxi Univ Tradit Chinese Med, Sch Chinese Med & Food Engn, Jinzhong, Shanxi, Peoples R China
[3] Chinese Acad Sci, Inst Proc Engn, State Key Lab Biochem Engn, Beijing, Peoples R China
来源
ENGINEERING IN LIFE SCIENCES | 2021年 / 21卷 / 06期
基金
中国国家自然科学基金;
关键词
hepatitis B core; molecular dynamic simulation; protein characterization; protein purification; virus‐ like particle; INDUCED EPITOPIC SUPPRESSION; ESCHERICHIA-COLI; TRYPTOPHAN FLUORESCENCE; VACCINE; SURFACE; PROTEINS; CARRIER; CHROMATOGRAPHY; GENERATION; EXPRESSION;
D O I
10.1002/elsc.202000104
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Inserting foreign epitopes to hepatitis B core (HBc) virus-like particles (VLPs) could influence the molecular conformation and therefore vary the purification process. In this study, a cost-effective purification process was developed for two chimeric HBc VLPs displaying Epstein-Barr nuclear antigens 1 (EBNA1), and hepatitis C virus (HCV) core. Both chimeric VLPs were expressed in soluble form with high production yields in Escherichia coli. Molecular dynamic (MD) simulation was employed to predict the stability of chimeric VLPs. HCV core-HBc was found to be less stable in water environment compared with EBNA1-HBc, indicating its higher hydrophobicity. Assisting with MD simulation, ammonium sulfate precipitation was optimized to remove host cell proteins with high target protein recovery yields. Moreover, 99% DNA impurities were removed using POROS 50 HQ chromatography. In characterization measurement, we found that inserting HCV core epitope would reduce the ratio of alpha-helix of HCV core-HBc. This could be another reason on the top of its higher hydrophobicity predicted by MD simulation, causing its less stability. Tertiary structure, transmission electron microscopy, and immunogenicity results indicate that two chimeric VLPs maintained correct VLP structure ensuring its bioactivity after being processed by the developed cost-effective purification approach.
引用
收藏
页码:438 / 452
页数:15
相关论文
共 50 条
  • [1] Production and purification of chimeric HBc virus-like particles carrying influenza virus LAH domain as vaccine candidates
    Kazaks, Andris
    Lu, I-Na
    Farinelle, Sophie
    Ramirez, Alex
    Crescente, Vincenzo
    Blaha, Benjamin
    Ogonah, Olotu
    Mukhopadhyay, Tarit
    De Obanos, Mapi Perez
    Krimer, Alejandro
    Akopjana, Inara
    Bogans, Janis
    Ose, Velta
    Kirsteina, Anna
    Kazaka, Tatjana
    Stonehouse, Nicola J.
    Rowlands, David J.
    Muller, Claude P.
    Tars, Kaspars
    Rosenberg, William M.
    BMC BIOTECHNOLOGY, 2017, 17
  • [2] Production and purification of chimeric HBc virus-like particles carrying influenza virus LAH domain as vaccine candidates
    Andris Kazaks
    I-Na Lu
    Sophie Farinelle
    Alex Ramirez
    Vincenzo Crescente
    Benjamin Blaha
    Olotu Ogonah
    Tarit Mukhopadhyay
    Mapi Perez de Obanos
    Alejandro Krimer
    Inara Akopjana
    Janis Bogans
    Velta Ose
    Anna Kirsteina
    Tatjana Kazaka
    Nicola J. Stonehouse
    David J. Rowlands
    Claude P. Muller
    Kaspars Tars
    William M. Rosenberg
    BMC Biotechnology, 17
  • [3] Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2
    Upasana Arora
    Poornima Tyagi
    Sathyamangalam Swaminathan
    Navin Khanna
    Journal of Nanobiotechnology, 10
  • [4] Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2
    Arora, Upasana
    Tyagi, Poornima
    Swaminathan, Sathyamangalam
    Khanna, Navin
    JOURNAL OF NANOBIOTECHNOLOGY, 2012, 10
  • [5] Hepatitis E Virus Capsid as a Carrier of Exogenous Antigens for the Development of Chimeric Virus-Like Particles
    Lu, Tianyu
    Behloul, Nouredine
    Zhou, Yi
    Baha, Sarra
    Liu, Zhenzhen
    Wei, Wenjuan
    Shi, Rui-Hua
    Meng, Jihong
    INTERVIROLOGY, 2022, 65 (01) : 37 - 48
  • [6] Photodynamic Therapy in Combination with the Hepatitis B Core Virus-like Particles (HBc VLPs) to Prime Anticancer Immunity for Colorectal Cancer Treatment
    Hao, Yang
    Gu, Zili
    Yu, Zhenfeng
    Schomann, Timo
    Sayedipour, Sana
    Aguilar, Julio C.
    ten Dijke, Peter
    Cruz, Luis J.
    CANCERS, 2022, 14 (11)
  • [7] An automated microscale chromatographic purification of virus-like particles as a strategy for process development
    Wenger, Marc D.
    DePhillips, Peter
    Price, Colleen E.
    Bracewell, Daniel G.
    BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, 2007, 47 (02) : 131 - 139
  • [8] Screen of multifunctional monoclonal antibodies against hepatitis B core virus-like particles
    Sun, Chang
    Ding, Fei-Xiang
    Wang, Fang
    He, Xiao-Wen
    He, Ying
    Li, Zhao-Shen
    Sun, Shu-Han
    MICROBIOLOGY AND IMMUNOLOGY, 2009, 53 (06) : 340 - 348
  • [9] Hepatitis B core-based virus-like particles to present heterologous epitopes
    Roose, Kenny
    De Baets, Sarah
    Schepens, Bert
    Saelens, Xavier
    EXPERT REVIEW OF VACCINES, 2013, 12 (02) : 183 - 198
  • [10] Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies
    Vietheer, Patricia T. K.
    Boo, Irene
    Drummer, Heidi E.
    Netter, Hans-Juergen
    ANTIVIRAL THERAPY, 2007, 12 (04) : 477 - 487